FY2025 EPS Estimate for PTC Therapeutics Lifted by Analyst

PTC Therapeutics, Inc. (NASDAQ:PTCT) – Analysts at Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for shares of PTC Therapeutics in a research report issued to clients and investors on Tuesday, March 4th. Cantor Fitzgerald analyst K. Kluska now expects that the biopharmaceutical company will post earnings per share of ($2.74) for the year, up from their previous forecast of ($3.26). Cantor Fitzgerald currently has a “Overweight” rating and a $113.00 price target on the stock. The consensus estimate for PTC Therapeutics’ current full-year earnings is ($4.52) per share.

A number of other research analysts have also issued reports on the stock. Royal Bank of Canada raised their price objective on shares of PTC Therapeutics from $60.00 to $63.00 and gave the company an “outperform” rating in a report on Tuesday, February 18th. Morgan Stanley raised shares of PTC Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $45.00 to $67.00 in a research note on Friday, December 13th. The Goldman Sachs Group boosted their price objective on shares of PTC Therapeutics from $32.00 to $42.00 and gave the stock a “sell” rating in a research note on Wednesday, December 4th. StockNews.com lowered PTC Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, February 17th. Finally, Robert W. Baird upped their price target on PTC Therapeutics from $52.00 to $70.00 and gave the company an “outperform” rating in a research report on Tuesday, December 3rd. Three investment analysts have rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $62.08.

PTC Therapeutics Trading Up 1.7 %

PTC Therapeutics stock opened at $52.80 on Thursday. The stock has a 50-day moving average price of $47.71 and a two-hundred day moving average price of $42.72. PTC Therapeutics has a 12 month low of $24.00 and a 12 month high of $55.60. The company has a market capitalization of $4.07 billion, a PE ratio of -8.89 and a beta of 0.62.

Insider Buying and Selling

In related news, VP Mark Elliott Boulding sold 1,543 shares of the company’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $45.34, for a total value of $69,959.62. Following the sale, the vice president now owns 108,846 shares in the company, valued at $4,935,077.64. This represents a 1.40 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Allan Steven Jacobson sold 1,230 shares of the firm’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $51.52, for a total transaction of $63,369.60. Following the completion of the transaction, the director now directly owns 19,118 shares in the company, valued at approximately $984,959.36. The trade was a 6.04 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,870 shares of company stock valued at $1,075,657. 5.50% of the stock is owned by company insiders.

Institutional Trading of PTC Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of PTC Therapeutics during the fourth quarter valued at approximately $4,891,000. Mackenzie Financial Corp raised its position in PTC Therapeutics by 132.2% in the fourth quarter. Mackenzie Financial Corp now owns 22,776 shares of the biopharmaceutical company’s stock worth $1,028,000 after acquiring an additional 12,967 shares during the period. Toronto Dominion Bank purchased a new position in PTC Therapeutics in the fourth quarter valued at about $148,363,000. GF Fund Management CO. LTD. bought a new position in shares of PTC Therapeutics during the 4th quarter valued at approximately $73,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of PTC Therapeutics by 19.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 160,251 shares of the biopharmaceutical company’s stock valued at $7,234,000 after acquiring an additional 26,274 shares during the period.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.